Clinical Trial Update: Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the theragnostic value of osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer; the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: University Hospital, Essen | Conditions: NSCLC, EGFR T790M | Phase 2 | Status: COMPLETED